DEUTERIUM-ENRICHED ANIDULAFUNGIN
The present application describes deuterium-enriched anidulafungin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
1 . A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 73 are independently selected from H and D; and
the abundance of deuterium in R 1 -R 73 is at least 1%.
2 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 73 is selected from at least 1%, at least 3%, at least 8%, at least 14%, at least 19%, at least 25%, at least 30%, at least 36%, at least 47%, at least 52%, at least 58%, at least 63%, at least 68%, at least 74%, at least 79%, at least 85%, at least 90%, at least 96%, and 100%.
3 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 14 is selected from at least 7%, at least 14%, at least 21%, at least 29%, at least 36%, at least 43%, at least 50%, at least 57%, at least 64%, at least 71%, at least 79%, at least 86%, at least 93%, and 100%.
4 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 15 -R 33 is selected from at least 5%, at least 11%, at least 16%, at least 21%, at least 26%, at least 32%, at least 37%, at least 42%, at least 47%, at least 53%, at least 58%, (k) at least 63%, at least 68%, at least 74%, at least 79%, at least 84%, at least 89%, at least 95%, and 100%.
5 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 34 -R 56 is selected from at least 4%, at least 9%, at least 13%, at least 17%, at least 22%, at least 26%, at least 30%, at least 35%, at least 39%, at least 43%, at least 48%, at least 52%, at least 57%, at least 61%, at least 65%, at least 70%, at least 74%, at least 78%, at least 83%, at least 87%, at least 91%, at least 96%, and 100%.
6 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 34 -R 37 is selected from at least 25%, at least 50%, at least 75%, and 100%.
7 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 38 -R 41 is selected from at least 25%, at least 50%, at least 75%, and 100%.
8 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 38 -R 45 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.
9 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 42 -R 45 is selected from at least 25%, at least 50%, at least 75%, and 100%.
10 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 46 -R 56 is selected from at least 9%, at least 18%, at least 27%, at least 36%, at least 45%, at least 56%, at least 64%, at least 73%, at least 82%, at least 91%, and 100%.
11 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 1-9 of Table 1.
12 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 10-18 of Table 2.
13 . An isolated deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 73 are independently selected from H and D; and
the abundance of deuterium in R 1 -R 73 is at least 1%.
14 . An isolated deuterium-enriched compound of claim 13 , wherein the compound is selected from compounds 1-9 of Table 1.
15 . An isolated deuterium-enriched compound of claim 13 , wherein the compound is selected from compounds 10-18 of Table 2.
16 . A mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:
wherein R 1 -R 73 are independently selected from H and D; and
the abundance of deuterium in R 1 -R 73 is at least 1%.
17 . A mixture of deuterium-enriched compound of claim 16 , wherein the compound is selected from compounds 1-9 of Table 1.
18 . A mixture of deuterium-enriched compound of claim 16 , wherein the compound is selected from compounds 10-18 of Table 2.
19 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.
20 . A method for treating invasive Aspergillus infection comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.